Alector News Releases http://investors.alector.com/ Alector News Releases en Alector Reports Recent Business Highlights and First Quarter 2019 Financial Results http://investors.alector.com/news-releases/news-release-details/alector-reports-recent-business-highlights-and-first-quarter Dosed first frontotemporal dementia patient with AL001 in the Phase 1b portion of the INFRONT clinical study Dosed first Alzheimer’s disease patient with AL002 in the Phase 1b portion of the INVOKE clinical study Initiated Phase 1 first-in-human clinical trial of AL003, called the INTERCEPT study Mon, 13 May 2019 16:05:00 -0400 Alector News Releases 6586 Alector to Present at the Bank of America Merrill Lynch Healthcare Conference on May 15, 2019 http://investors.alector.com/news-releases/news-release-details/alector-present-bank-america-merrill-lynch-healthcare-conference SOUTH SAN FRANCISCO, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced that members of the management team will present at Wed, 08 May 2019 16:05:00 -0400 Alector News Releases 6581 Alector Announces First Alzheimer’s Disease Patient Dosed in Phase 1b Study of AL002 http://investors.alector.com/news-releases/news-release-details/alector-announces-first-alzheimers-disease-patient-dosed-phase - Phase 1b study of AL002 enrolling Alzheimer’s disease patients will assess safety and pharmacodynamics, and will monitor target specific biomarkers SOUTH SAN FRANCISCO, Calif. , May 06, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering Mon, 06 May 2019 06:30:00 -0400 Alector News Releases 6571 Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001 http://investors.alector.com/news-releases/news-release-details/alector-announces-first-frontotemporal-dementia-patient-dosed Phase 1 healthy volunteer portion of the AL001 study successfully met its primary objective of safety and demonstrated proof-of-mechanism in the central nervous system (CNS) Phase 1b study of AL001 enrolling frontotemporal dementia ( FTD ) patients with a mutation in the progranulin gene will Wed, 17 Apr 2019 16:05:00 -0400 Alector News Releases 6566 Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease http://investors.alector.com/news-releases/news-release-details/alector-initiates-phase-1-trial-al003-treatment-patients - AL003 is Alector’s second program targeting Alzheimer’s disease and its third program in the clinic SOUTH SAN FRANCISCO, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for Mon, 01 Apr 2019 16:30:00 -0400 Alector News Releases 6561 Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results http://investors.alector.com/news-releases/news-release-details/alector-reports-recent-business-highlights-and-fourth-quarter - Strong 2018 marked by the company’s first and second programs entering the clinic, targeting frontotemporal dementia and Alzheimer’s disease. Ten programs in Research and Development and two in Pre-Clinical Development advancing towards the clinic. - Data from the first program validated Tue, 26 Mar 2019 16:15:00 -0400 Alector News Releases 6536 Alector to Present at Investor Conferences in March http://investors.alector.com/news-releases/news-release-details/alector-present-investor-conferences-march SOUTH SAN FRANCISCO, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration today announced that members of the management team will present at Wed, 06 Mar 2019 17:15:00 -0500 Alector News Releases 6521 Alector Announces Pricing of Initial Public Offering http://investors.alector.com/news-releases/news-release-details/alector-announces-pricing-initial-public-offering SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the pricing of its initial public offering of Wed, 06 Feb 2019 19:59:00 -0500 Alector News Releases 6401 Alector Strengthens Board of Directors with Appointments of David Wehner, Richard Scheller and Louis Lavigne http://investors.alector.com/news-releases/news-release-details/alector-strengthens-board-directors-appointments-david-wehner SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, today announced the following additions to its board as independent directors:   David Wehner, Chief Fri, 16 Nov 2018 00:00:00 -0500 Alector News Releases 6221 Alector Initiates Phase 1 Trial of AL002 for the Treatment of Patients with Alzheimer’s Disease http://investors.alector.com/news-releases/news-release-details/alector-initiates-phase-1-trial-al002-treatment-patients First Clinical Trial of a Program Designed to Address Multiple Brain Pathologies in Alzheimer’s Disease by Reversing Immune Dysfunction SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Alector, a privately held biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the Thu, 15 Nov 2018 00:00:00 -0500 Alector News Releases 6226